Managing Operational Challenges In CAR-T Clinical Trial Logistics

By Sachit Verma, MD, MBA, FACHE, FAPCR

CAR-T cell therapy trials present unique operational challenges for clinical sites. From coordinating apheresis and manufacturing schedules to managing cryogenic storage and staffing specialized teams, sites must navigate complex logistics to ensure patient safety and trial success. This article highlights the key day-to-day operational considerations and challenges clinical trial supply leaders need to be aware of when managing CAR-T trials.

The execution of CAR-T cell therapy entails more than just logistics such as shipping and receiving; it involves coordinating various components to ensure smooth operations. Unlike conventional treatments, CAR-T therapy is tailored to each individual and demands personalized processing. This underscores the need for stringent protocols at the clinical facility when collecting samples, transporting them, manufacturing the therapy, and administering it to prevent errors and ensure the therapy's safety and effectiveness.

Effective management of CAR-T clinical trials is vital to ensure a smooth process from start to finish. This involves comprehensive staff training to ensure proper handling, maintenance of chain of custody (COC), and adherence to regulatory standards. With the need for cryogenic storage at extremely low temperatures, strict material handling procedures are essential. This includes thorough inspections upon receipt and controlled thawing protocols led by the pharmacy. In addition, successful trial execution entails simulated runs and thorough monitoring for 30 days post-infusion to prioritize patient safety, enhance outcomes, maintain data integrity, and achieve trial objectives. It is crucial to acknowledge the importance of logistics in CAR-T trials, with site responsibilities and material handling practices impacting all trial aspects significantly. By emphasizing the interplay between these elements, trial success can be optimized.

All sites must consider and address the following challenges and associated considerations when planning operations.

1. Capacity And Scheduling Limitations

• Alignment of Apheresis and Manufacturing Slots: It is essential for sites to synchronize the timing of a patient's apheresis procedure with an open slot at the manufacturing facility. Changes in the patient's health status or delays in courier services may lead to the site forfeiting the slot, resulting in treatment delays lasting several weeks.

To ensure proper alignment between apheresis and manufacturing slots, sites must reserve a slot in advance. This often needs to be done weeks before the patient completes screening. For processes requiring fresh cells, the cells must reach the manufacturing facility within 24 to 48 hours of collection. If apheresis takes place on a Wednesday, the manufacturing facility should be prepared to begin the wash and spike process by Thursday morning. To account for potential delays such as courier issues or inclement weather, high-performing sites often schedule apheresis 24 hours before the manufacturing start date. This allows for buffer days without risking loss of cell viability.

• Inpatient Bed Allocation: CAR-T therapy patients often require specialized ICU or oncology beds for post-infusion monitoring. Logistics issues can lead to either "bed-blocking" or situations where the drug arrives but no appropriate bed is available for the patient.

2. Infrastructure And Specialized Handling

• Cryogenic Storage: Numerous locations face challenges with limited space for liquid nitrogen (LN2) dewars (cryogenic dry shippers). Proper maintenance of these tanks necessitates trained personnel and adherence to rigorous safety procedures to mitigate the risk of nitrogen asphyxiation or "freeze” or cryogenic burns. Working with materials in extremely low temperatures carries substantial operational hazards that require the utmost caution and compliance with safety procedures. 

Proper personal protective equipment (PPE) and training are crucial for employees operating in these conditions. This includes specialized gear such as cryogenic gloves, face shields, and aprons to shield against potential dangers like dry-ice burns or LN2 splashes. Monitoring oxygen levels is also critical, with LN2 tanks fitted with sensors that can detect oxygen levels in the event of leaks, activating alarms to prevent asphyxiation risks. There is also a crucial emphasis on managing the risk of transient warming, as even a brief exposure to room temperature during material transfer can trigger a harmful micro-thaw phenomenon that affects cell membranes. Therefore, it is crucial to prioritize safety measures and handle procedures quickly and accurately.

• Equipment Calibration: Sites must guarantee the validation and calibration of on-site freezers and monitoring systems. A malfunction in a local freezer is equally detrimental as a mishap during transportation. Calibrating equipment in clinical trial supply chains is important. It helps make sure that the investigational medicinal products stay effective. Keeping things like ultra-low freezers and refrigerators calibrated is key to keeping products safe and effective. Having properly calibrated thermometers and pH meters is essential for verifying the stability and dissolution of drugs in research. Calibration is crucial for maintaining the reliability and validity of our results, as well as ensuring sterility and preventing contamination. Regular calibration is necessary to ensure accuracy and reliability in our work.

3. Chain Of Identity (COI)

• Manual Labeling Risks: Some sites still depend on manual paperwork and labeling, despite the trend toward digital processes. Any mismatch between the patient ID at the time of collection and the product ID during infusion is deemed a serious error that could impede the trial's advancement. In a clinical trial setting, integrating COI is crucial for safety and integrity of personalized medicines, especially cell and gene therapies. COI links patients to treatment, ensuring precise administration of therapies from a patient's material. Three main COI elements — unique identifier, bidirectional link, anonymized tracking — oversee the treatment process comprehensively. Using anonymized references instead of personal data, COI protects confidentiality while allowing efficient monitoring of the therapy's journey, boosting credibility of personalized medicine trials.

 4. Variability Of Cellular Products

• Occurrence of Out-of-Specification (OOS) Results: There are instances where the manufactured cells do not meet the potency or purity standards required for the trial. ¹  In such cases, sites must handle the logistics of a rescue collection or navigate the intricate regulatory process for administering an OOS product under compassionate use protocols. The variability of cellular products, commonly known as living drugs, such as CAR T cells, presents specific challenges due to biological and process-related inconsistencies in the final therapeutic product. In contrast to traditional chemically synthesized drugs, these living products derived from organisms are highly susceptible to fluctuations that can impact clinical trial supply and product management. This variability requires a shift from the conventional stock-and-ship supply model (centralized pharmaceutical supply chain in which products are produced in large batches using healthy donor cells and then cryopreserved and maintained as inventory for prompt utilization) to a more agile just-in-time approach, leading to issues like unpredictable yields that hinder precise dose scheduling. In response to the JIT challenges, the industry is transitioning to decentralized and automated solutions, utilizing closed, software-controlled systems. The supply chains for autologous products require a scale-out strategy, increasing operational complexity and introducing a heightened risk of waste due to decreased yields or subpar batches. ¹ Effective trial product management requires specialist systems that include COI and custody tracking systems, real-time monitoring using Internet of Things (IoT) sensors, and comparability assessments. These systems ensure safety, efficacy, and compliance with regulations in the ever-changing field of cellular therapy.

5. Staffing Challenges In CAR-T Therapy

• Specialized Workforce Shortage: The administration of CAR-T therapy requires a team of highly skilled professionals such as apheresis nurses, cell therapy coordinators, and specialized pharmacists. However, many healthcare facilities are experiencing difficulties in finding and retaining qualified staff, leading to high turnover rates. Additionally, each new hire must undergo extensive GTP training before they are able to handle study-specific products. The CAR-T cell clinical trial logistics lack a specialized workforce for the vein-to-vein supply chain. Insufficient staffing delays the process and affects patient care. The shortage of clinical supply coordinators leads to missed manufacturing opportunities and prolonged wait times for patients, impacting disease progression. Staffing issues increase critical data errors, affecting batch usability. Inadequate cold chain training raises the risk of temperature deviations, making drugs ineffective. Site capacity decreases due to staffing challenges, affecting trial enrollment and patient supply management.
• 24/7 Logistics Concerns: Timely delivery of CAR-T therapy shipments can be a challenge, as they do not always align with traditional work hours. Clinical facilities often struggle with ensuring adequate staffing for after-hours shipments to receive cryogenic shippers, which may arrive in the middle of the night. This is crucial to prevent any breach in the chain of custody (COC) by unauthorized personnel.

6. Space Constraints And Dewar Management

• Physical Space: The storage of dewars can pose a significant issue for healthcare facilities. In a busy site conducting multiple CAR-T trials simultaneously, the accumulation of five, 10, or15 large dewars in hallways or pharmacies can create a hazardous environment in terms of fire safety and present logistical challenges for space-limited hospitals. Effective storage planning is a key factor in ensuring the smooth administration of patient infusion therapies within the manufacturing process. When determining facility suitability, trial sponsors must ensure that each site meets specific requirements for space, equipment, and scheduling. Coordination of storage plans with treatment phases, such as lymphodepletion, is crucial. Redundancy planning, including backup freezers and generators, is essential to mitigate risks of equipment failure that could impact patient therapies. Additionally, a reliable inventory tracking system should be implemented to maintain COI and COC, ensuring accurate delivery of cells to the correct patient.
• Return of Empty Shippers: It is the responsibility of the site to prepare the empty dewar for the return courier. Failure to properly label or notify the pickup could result in the site being charged daily holding fees by the logistics provider.

7. Patient Travel And Accommodations

• Logistics of Proximity: Patients frequently travel long distances to receive CAR-T therapy at accredited sites. The site's logistics team often acts as a travel coordinator, organizing patient accommodations and local transportation and ensuring that the patient stays close to the hospital for several weeks after treatment for monitoring and managing potential complications such as cytokine release syndrome (CRS).

8. Quality Control (QC) Enforcement

• Thawing Issues: A significant risk factor arises during the thawing process directly at the treatment location. In cases where the water bath or automatic thawing equipment is not accurately calibrated, there is a possibility of cells being either overcooked or partially frozen, leading to potential negative impacts on patient results.² The QC enforcement process in CAR-T clinical trials is a carefully coordinated effort that combines cGMP/cGTP standards and strict COC/COI logistics that act as critical safeguards to prevent serious mix-ups from occurring. ^3,4  Each aspect of trial material handling and logistics plays a crucial role in the success of CAR-T trials, as the therapy involves patient-specific cells that have a limited lifespan. From collecting leukapheresis products at the clinic to transporting them in liquid nitrogen dewars and maintaining end-to-end tracking through COC procedures, every step is vital to ensure the correct cells are delivered to the intended patient. The focus on maintaining cGTP compliance and FACT accreditation at treatment sites highlights the rigorous professional standards maintained during CAR-T clinical trials.
• Supply Reconciliation: Treatment sites are responsible for monitoring and maintaining an inventory of specialized collection kits. If a kit expires or is missing a specific anticoagulant tube, the entire collection process (and the patient's treatment slot) may need to be cancelled.

Successfully managing day-to-day CAR-T trial operations requires careful attention to site logistics, staffing, patient support, and material handling. By proactively addressing these operational challenges, clinical trial supply leaders can help ensure smooth trial execution, minimize delays, and maintain patient safety and product integrity. In my next article, I will explore how compliance, site readiness, and budgeting considerations further impact the successful execution of CAR-T trials.

References:

1. Magdi Elsallab, & Maus, M. V. (2023). Expanding access to CAR T cell therapies through local manufacturing. Nature Biotechnology, 41(12), 1698–1708. 
2. Kilbride, P., Meneghel, J., Creasey, G., Masoudzadeh, F., Drew, T., Creasey, H., Bloxham, D., Morris, G. J., & Jestice, K. (2020). Automated dry thawing of cryopreserved haematopoietic cells is not adversely influenced by cryostorage time, patient age or gender. PloS one, 15(10), e0240310.
3. Rouce, R. H. (2025). Clearing the hurdles for CAR-T cell treatment. Nature Reviews Immunology, 25(11), 777–779.
4. Cell and Gene Therapy Quality Control & Assurance: Testing, Compliance, and Future Trends. (2024). Cellandgene.com. https://www.cellandgene.com/topic/cell-gene-therapy-qa-qc

About The Author:

Sachit Verma, MD, MBA, FACHE, FAPCR, is a board-certified healthcare leader with a diverse background in clinical research operations, administration, revenue cycle management, and compliance. Utilizing his expertise in clinical research, Dr. Verma has spearheaded systemwide initiatives to streamline trial delivery processes, uphold financial stewardship, and enhance operational efficiency by optimizing data analysis, budget management, and project life cycles. Dr. Verma possesses a diverse skill set in overseeing contracts, grants, feasibility assessments, study start-up initiatives, patient recruitment, enrollment and retention strategies, quality and performance improvement, and technology implementations.  Additionally, he is a successful author, speaker, mentor, and board member who combines leadership, regulatory knowledge, and best practices to ensure the success of projects and clinical operations.